iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Alembic receives USFDA tentative approval for Fesoterodine Fumarate ER Tablets

4 Feb 2022 , 01:32 AM

Alembic Pharmaceuticals today announced that it has received tentative approval from the US Food Drug Administration USFDA for its Abbreviated New Drug Application ANDA for Fesoterodine Fumarate Extended Release Tablets 4 mg and 8 mg The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product RLD Toviaz Extended-Release Tablets 4 mg and 8 mg of Pfizer Inc Pfizer Fesoterodine Fumarate ExtendedRelease Tablets are indicated for the treatment of overactive bladder OAB in adults with symptoms of urge urinary incontinence urgency and frequency It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses Fesoterodine Furnarate Extended-Release Tablets 4 mg and 8 mg have an estimated market size of US$ 225 million for twelve months ending September 2021 according to IQVIA

Related Tags

  • Announcements
  • BSE
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.